Tango Therapeutics, Inc.
Tango Therapeutics, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on October 15, 2026, a projected date rather than a confirmed one. There are 4 upcoming events on record.
Cash runway is approximately 68.6 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
| Date | Event | Type | Phase |
|---|---|---|---|
| October 15, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| March 31, 2027 | Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss | Trial Milestone | Phase 1/Phase 2 |
| June 15, 2027 | Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors | Trial Milestone | Phase 1/Phase 2 |
| June 15, 2027 | Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients | Trial Milestone | Phase 1/Phase 2 |
Track TNGX alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open TNGX in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.